CompletedNot Applicable

Soluble CD95 Ligand Role in the Pathophysiology of Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis

France48 participantsStarted 2018-12-14

Plain-language summary

The study aims at defining the role of soluble CD95 Ligand in the physiopathology of a rare group of inflammatory diseases: ANCA associated vasculitis. Soluble CD95 Ligand might have a prognostic and diagnostic interest as well as potential for the discovery of new therapeutic strategies.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosis of ANCA associated vasculitis according to the Chapel-Hill Consensus Conference - 2012 modified version * Age ≥ 18 years * being affiliated to health insurance * willing to participate and to sign informed consent. Exclusion Criteria: * Pregnant or breastfeeding women, * patient concerned by articles L 1121-5 to L 1121-8 (persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent)

What they're measuring

Change of quantitative levels of s-CD95-L in ANCA associated vasculitis between baseline and Month 12

Timeframe: At baseline (Day 0) and 12 months from baseline

Trial details

NCT IDNCT03698071

SponsorUniversity Hospital, Bordeaux

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-09-18

View on ClinicalTrials.gov More ANCA Associated Vasculitis trials